Table 3.
Monotherapy persistence on index TNFi
| Persistent on monotherapy after discontinuing csDMARD, n (%) | ETN monotherapy | Other TNFi monotherapy | Risk difference % (95% CI) | p value |
|---|---|---|---|---|
| 6-month cohort | ||||
| bDMARD-naïve | 84 (58) | 125 (46) | 11.9 (2.0, 21.9) | 0.02 |
| bDMARD-experienced | 18 (50) | 70 (43) | 6.5 (− 11.5, 24.6) | 0.48 |
| All patients (stratified)a | 10.8 (2.1, 19.6) | 0.02 | ||
| 12-month cohort | ||||
| bDMARD-naïve | 46 (47) | 72 (36) | 11.1 (− 0.8, 23.0) | 0.07 |
| bDMARD-experienced | 9 (41) | 30 (28) | 12.6 (− 9.7, 34.9) | 0.24 |
| All patients (stratified)b | 11.4 (0.9, 21.9) | 0.03 | ||
bDMARD, biologic disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; ETN, etanercept; OR, odds ratio; TNFi, tumor necrosis factor inhibitor
aMantel–Haenszel test of homogeneity reveals that the risk differences between the bDMARD-naïve and bDMARD-experienced patients were not significantly different (p = 0.61)
bMantel–Haenszel test of homogeneity reveals that the risk differences between the bDMARD-naïve and bDMARD-experienced patients were not significantly different (p = 0.85)